Vaccine adjuvants as potential cancer immunotherapeutics.
Vaccine adjuvants as potential cancer immunotherapeutics.
复制标题
DOI：
10.1093/intimm/dxw015
复制
发表时间：
2016-07
影响因子：
4.4
通讯作者：
Ishii KJ
中科院分区：
文献类型：
--
作者：
Temizoz B;Kuroda E;Ishii KJ
从各种临床试验和动物研究中获得的累积证据表明，癌症疫苗需要比目前许可的佐剂更好的佐剂，其中包括最常用的明矾和不完全弗氏佐剂，因为缺乏有效的抗肿瘤免疫或诱导不希望的免疫。使用免疫刺激佐剂，特别是TLR、C型凝集素受体、视黄酸诱导基因I样受体和干扰素基因刺激物的激动性和非激动性配体的几项临床试验已经揭示了它们不仅作为疫苗佐剂而且作为抗肿瘤剂的治疗潜力。最近，这种免疫刺激或免疫调节佐剂的组合已经显示出优于其单一用途的上级功效，这表明寻求目前可用或充分表征的佐剂的最佳组合可以为开发用于癌症免疫治疗的新型佐剂提供更好的机会。
New adjuvants for cancer immunotherapy Accumulated evidence obtained from various clinical trials and animal studies suggested that cancer vaccines need better adjuvants than those that are currently licensed, which include the most commonly used alum and incomplete Freund’s adjuvant, because of either a lack of potent anti-tumor immunity or the induction of undesired immunity. Several clinical trials using immunostimulatory adjuvants, particularly agonistic as well as non-agonistic ligands for TLRs, C-type lectin receptors, retinoic acid-inducible gene I-like receptors and stimulator of interferon genes, have revealed their therapeutic potential not only as vaccine adjuvants but also as anti-tumor agents. Recently, combinations of such immunostimulatory or immunomodulatory adjuvants have shown superior efficacy over their singular use, suggesting that seeking optimal combinations of the currently available or well-characterized adjuvants may provide a better chance for the development of novel adjuvants for cancer immunotherapy.